Genmab A/S (GMAB) announced that worldwide net trade sales of Darzalex, including sales of the subcutaneous product, as reported by J&J (JNJ) were $11.67B in 2024. Net trade sales were $6.588B in the U.S. and $5.082B in the rest of the world. Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and SC products, under the exclusive worldwide license to J&J to develop, manufacture and commercialize daratumumab.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab upgraded to Market Perform from Underperform at Bernstein
- Genmab announces results from ongoing clinical trials of epcoritamab
- Genmab announces new results from Phase 1b/2 EPCORE NHL-2 trial
- Genmab A/S Expands Share Capital and Warrants
- Genmab Increases Capital Through Employee Warrant Exercise